Nevro reports Q4 EPS ($1.41), consensus (75c)

Reports Q4 revenue $105.5M, consensus $102.61M. Cash, cash equivalents and short-term investments totaled $292.5M as of December 31, 2024, an increase of $15.5M from September 30, 2024. “We are pleased that adjusted EBITDA for the FY24 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings,” said Kevin Thornal, Nevro’s (NVRO) president and CEO. “Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free patients from the burden of chronic pain.”